BASi Signs Reseller Agreement With LABEX of MA for Refurbished Culex® Automated Blood Sampling Systems

Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”), a recognized global leader in the development of instrumentation for automated blood sampling in animal models, today announced that it has entered into a reseller agreement with LABEX of MA (“LABEX”) for refurbished BASi Culex® Automated Blood Sampling Systems.

BASi Culex Automated Blood Sampling Systems deliver programmable, continuous, automated blood microsampling that provides a full pharmacokinetic curve from a single, fully conscious, freely-moving animal. The system allows for the simultaneous collection of multiple data streams such as blood, bile, metabolites, dialysates and more. LABEX is a leading source of reconditioned and used animal caging and vivarium equipment.

“We couldn’t be more pleased to be partnering with LABEX as a reseller of our refurbished Culex systems given their industry experience, a broad network of loyal customers, and exceptional client care,” said Alan Loch, Director of Business Development for BASi. “Our Culex systems perfectly complement LABEX’s already incomparable array of high-quality, reconditioned and used vivarium equipment.”

Ed Russo, President of LABEX of MA said, “Everyone here at LABEX is excited about our recent partnership with BASi. We are hopeful it will open many doors for us while we are able to help our customers purchase top-notch blood sampling systems.”

About LABEX of MA

 LABEX of MA brings together a unique combination of industry experience and unmatched inventory for providing the best choice for reconditioned vivarium equipment. The Company’s tremendous industry experience and broad network makes them uniquely qualified to understand the needs and requirements of the university, research, pharmaceutical and biotechnology clients. Visit for more about LABEX of MA.

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit for more information about BASi.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.

Company Contact:

Jill Blumhoff 

Chief Financial Officer &

Vice President of Finance 

Phone: 765.497.8381 

Source: Bioanalytical Systems, Inc.


Additional Images